THE 2026
EUROPEAN ALDOSTERONE CONFERENCE MEETING
The 2026 European Aldosterone Conference meeting, co organized with INI-CRCT, will be held on October 16-17, 2026 in Kremlin-Bicêtre, near Paris, France, to provide the opportunity to meet and network with colleagues from Europe.
PROGRAM – DAY 1 – OCTOBER, 16
The 2026
European Aldosterone Conference meeting
13:30 – 13:50 : Official welcome by University Authorities
Mehran Mostafavi
Vice-President for Research, Paris-Saclay University
Marc Humbert
Dean of the Faculty of Medicine, Paris-Saclay University
13:50 – 14:00 : Welcome address – Maria-Christina Zennaro
14:00-14:40 : Keynote lecture – Mineralocorticoid pathway in ocular disease – Francine Behar-Cohen
Chair: Antoine Ouvrard-Pascaud
14:40 – 15:50 : SESSION 1
Pathophysiological roles of Aldosterone and Mineralocorticoid Receptor
(ALDO/MR) in cardio-renal disorders
Chairs: Johann Bauersachs & Maria-Christina Zennaro
14:40 – 15:05 : From Aldosterone to Arrhythmia:
MR drives Cardiac Remodeling and Atrial Fibrillation – Achim Lother
15:05 – 15:20 : A Novel NGAL-GAL3 Axis Emerges in Mineralocorticoid Receptor-Driven Aortic Valve Remodeling in Chronic Kidney Disease – Tania Sánchez-Bayuela
15:20 – 15:35 : The Mineralocorticoid Receptor Drives Inflammaging in Adipose Tissue Macrophages – Isaac Galuppo
15:35 – 15:50 : Multilevel microRNA-mediated regulation of mineralocorticoid signaling pathway during perinatal kidney development – Julie Perrot
15:50 – 17:20 : Poster session, coffee break and sponsor exhibition booths visit
Chairs: Sheerazed Boulkroun & Antoine Ouvrard-Pascaud
17:20-18:35 SESSION 2
Brian Harvey Young Investigator Competition
Chairs: Fabio Fernandes-Rosa & Kristina Kusche
17:20 – 17:35 : Effects of colonic smooth muscle cells-activated
mineralocorticoid receptor on intestinal epithelial barrier function: 2D vs. 3D in vitro models – Mathilde Leboutte
17:35 – 17:50 : Impact of adipocyte glucocorticoid signaling on adipose
tissue plasticity and metabolic disorders associated with glucocorticoid-induced lipodystrophy – Charlotte Letellier
17:50-18:05 : NR3C1 gene variants influencing glucocorticoid sensitivity – Margaux Laulhé
18:05 – 18:20 : Overactivation of mineralocorticoid pathway
aggravates UVB-induced corneal damages: restoration by spironolactone eyedrops – Linxin Zhu
18:20 – 18:35 : Enhanced mineralocorticoid receptor expression
in diabetic women is associated with valve calcification in aortic stenosis – Miriam Goñi-Olóriz
18:35 – 19:15 : Keynote lecture
Raphaëlle Castagné
Chair: Sheerazed Boulkroun
20:30 : Social dinner
PROGRAM – DAY 2 – OCTOBER, 17
9:00 – 9:40 : Keynote lecture
Mineralocorticoid receptor antagonists versus Aldosterone
synthase inhibitors : pathophysiological and clinical considerations
Michel Azizi, HEGP
Chair: Frédéric Jaisser
9.40-10:20 SESSION 3
Cutting-Edge Insights into Aldosterone Biosynthesis and Secretion
Chairs: Teresa Seccia & Bruno F
9:40 – 10:05 : Biomarkers of endocrine hypertension – personalized medicine, more than just aldosterone – Eleanor Davies
10:05 – 10:30 : From genetic determinants of primary aldosteronism to experimental animal models – Sheerazed Boulkroun
10:30 – 10:45 : Estrogen receptor B inhibits aldosterone synthase expression
through an ERB-NCO-DAX-1 repressor complex
Brasilina Caroccia
10:45 – 11:00 : miR-139-5p Acts as a Post-Transcriptional Gatekeeper
of Zona Glomerulosa Identity and Modulates Stimulated Aldosterone Biosynthesis
Xiaomin Li
11:40-12:50: SESSION 4
Mineralocorticoid and Glucocorticoid Receptors
Chairs: Say Viengchareun & Min Zhao
11:40 – 12:05 : Glucocorticoids as ligands for mineralocorticoid
receptors: receptor cross talk and brain function – Onno Meier
12:05 – 12:20 : New roles of corticosteroid receptors in Schwann cells and peripheral myelination – Damien Le Menuet
12:20 – 12:35 : Hepatic SGK1 Overexpression Promotes Lipid-Induced Hepatic
Fibrosis Independent ofSteatosis Severity – Diego Alvarez de la Rosa
12:35 – 12:50 : PELP1 acts as corepressor of activated mineralocorticoid receptors
Georg Stahl
14:00 – 15:20 SESSION 5
Innovations in Targeted Therapies – What’s Next?
Chairs: Massimiliano Caprio & Natalia López-Andrés
14:00 – 14:25 : Selective aldosterone synthase inhibition
with vicadrostat across the cardiorenal continuum – Johann Bauersachs
14:25 – 14:40 : In female mice with or without post-menopausal conditions and undergoing
weight-cycling, finerenone treatment during caloric restriction improves global
metabolism and prevents the development of HFpEF – Manon Monmirel
14:40 – 14:55 : Uremic toxins TMAO and phenylacetylglutamine promote valvular fibrocalcification through mineralocorticoid receptor signaling in aortic stenosis patients with chronic kidney disease – Susana San Ildelfonso-Garcia
14:55 – 16:05: SESSION 6
RAAS
Chairs: Eleanor Davies & Achim Lother
15:00 – 15:25 : Mechanisms of Vascular Inflammation and Potential Therapeutic Targets – Francisco Rios
15:25 – 15:50 : Cluster analysis of RAAS biomarkers informs antihypertensive
drug treatment and raised blood pressure – Luisa Foco
15:50 – 16:05 : An aldosterone–mineralocorticoid receptor regulatory loop maintains zona glomerulosa homeostasis and plasticity – May Fayad
16:05 – 16:15 Closing remarks : Frédéric Jaisser
Johann Bauersachs, Achim Lother
REGISTRATION IS OPEN
FOR ESAC 2026 !
Registration is open for ESAC 2026, which will be held on 16-17 October in Le Kremlin-Bicêtre. Registration will remain open until 4 October 2026. Please be aware that abstract submission and congress registration are separate processes. All participants, including authors who have submitted an abstract, must register independently to attend the congress.
We are also pleased to announce that the Late-Breaking abstract submission is now open until 4 October 2026.